Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000345644 | SCV000338388 | uncertain significance | not provided | 2016-01-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001309590 | SCV001499093 | uncertain significance | Cortical dysplasia-focal epilepsy syndrome | 2022-03-19 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with serine, which is neutral and polar, at codon 1144 of the CNTNAP2 protein (p.Thr1144Ser). This variant is present in population databases (rs775781258, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with CNTNAP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 285390). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV001309590 | SCV001519894 | uncertain significance | Cortical dysplasia-focal epilepsy syndrome | 2019-06-07 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |